The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA570588
Title Identification of New Substrates for Breast Tumor Specific LMW Cyclin E/CDK2 Kinase.
Publication Date Sep 2012
Media Count 18p
Personal Author S. Akli
Abstract Cyclin E overexpression occurs in 25% of breast cancer tumors and is linked to poor prognosis. In tumor cells full length cyclin E (FL-E) is processed by an elastase-like protease into low-molecular weight isoforms (LMW-E) that are biochemically hyperactive. We recently demonstrated in a transgenic mouse model that CDK2 is required for LMW-E-induced breast cancer. The hypothesis is that the biological and biochemical differences between FL-E and LMW-E may be due to the phosphorylation of a distinct set of substrates when complexed with CDK2. The Protoarray analysis led us to discover Hbo1 and CINP as novel substrates of the LMW-E/CDK2 complex that may mediate critical downstream signaling to contribute to the oncogenic potential of LMW-E in breast cancer. We will pursue the identification of new substrates by phosphorylating a cell lysate in vitro with cyclin EL/CDK2 (F80G) and cyclin ELMW/ CDK2 (F80G) and PE-ATP-(gamma)-S. The identification of new physiological LMW-E/CDK2 substrates will lead to the development of novel targets for therapeutics and the identification of the biological function for the treatment of the aggressive LMW-E expressing triple negative breast cancer.
Keywords Biochemistry
Breast cancer
Cells(Biology)
Neoplasms
Phosphorylation
Substrates
Transcription(Genetics)


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57F - Cytology, Genetics, & Molecular Biology
Corporate Author M.D. Anderson Cancer Center, Houston, TX.
Document Type Technical report
Title Note Final rept. 1 Sep 2010-31 Aug 2012.
NTIS Issue Number 1315
Contract Number W81XWH-10-1-0815

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader